Only weeks after the initial reports of unusual illnesses in Wuhan, China, the first US case of #coronavirus has been identified. Spread of this new virus brings to mind the 2003 SARS epidemic. How similar/different is this outbreak from SARS? Some thoughts.
No approved treatments or vaccines available for these two viruses, though scientists have been working on a SARS vaccine and started work on a novel coronavirus vaccine. Containment of SARS relied on infection control, isolation, quarantine and other non-pharmaceutical measures.
Screening of international travelers for fevers/signs of illness is an aspect of both responses. Canada and multiple Asian countries screened millions of passengers but did not find a case SARS that way. WHO recommends against border screening for identifying cases.
None of the international cases of the new coronavirus, including in the US, were identified through border screening. Currently the U.S. screens passengers in LA, NY, and SF. The case was identified in Washington state.
Both outbreaks have the potential to have an outsized economic impact, even with only a few cases. Globally, SARS caused an estimated $30 billion in economic losses, or about $3 million per case of the disease.
Outbreaks can be prone to misinformation or sensationalization, especially in the age of social media. People and regions that are affected can be stigmatized, which was an aspect of the SARS outbreak.
What about differences? The speed of identification of the virus in Wuhan, and the speed with which there has been international spread sets it apart from SARS. It took months to identify the causative agent of SARS, and for international spread to occur.
Hospital-associated infections were an important part of SARS; a large proportion of SARS cases were health workers and caregivers. So far, this has not been the case with the novel coronavirus, though China has reported a number of health worker infections more recently.
Chinese response capacity and transparency is another change. Most public health observers feel Chinese officials have been laudably open to sharing information about the current outbreak there, a change from what happened during SARS.
The pace of scientific discovery with this outbreak exceeds that of SARS. No effective, rapid test for SARS was available for the 6 months of the SARS epidemic. We already have a diagnostic for the new virus, just weeks after its discovery.
There are important things we still don’t know. The epidemiological characteristics of the new virus, such how easily it transmits and the likelihood that it causes severe disease, are not fully understood but are being studied.
SARS was quite severe, if not especially transmissible. It killed around 10-15% of those infected. Early indications are the new coronavirus seem to indicate a much less deadly virus, but again, we still don't have enough information.
CDC says screening will now expand to include two additional airports: Chicago and Atlanta (already screening at NYC, LA, and SF) washingtonpost.com/health/2020/01…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Wonderful: a malaria vaccine is now recommended for use in high burden areas, and could save tens of thousands of lives a year who.int/news/item/06-1…
(For sense of the timing: initial Phase 3 trial results for this vaccine were published a decade ago!) nejm.org/doi/10.1056/NE…
WHO and others careful to note the vaccine is best positioned as one component of a comprehensive public health approach to malaria prevention. It is burdensome (4 shots over 18 months) and perhaps 50% effective in preventing severe malaria in kids.
Unclear how quickly it can be rolled out in African countries given the resources focused on Covid-19 vaccine distribution.
“We’re really going to have to see how the pandemic unfolds next year in terms of when countries will be ready" nytimes.com/2021/10/06/hea…
In 2022, protein-based COVID-19 vaccines could be what mRNA vaccines have not been for many lower-income countries: accessible and relatively easy to manage. Slower out of the gate than other vaccines, there are now several candidates on the near horizon. 1/
They are refrigerator stable, have promising safety profiles, and efficacy that in many cases rivals mRNA vaccines. Protein vaccines are also readily scalable, with good prospects for technology transfer 2/ nature.com/articles/d4158…
Novavax, delayed for months with manufacturing and supply woes, recently filed for authorization in several countries and WHO for its protein-based vaccine. COVAX has already purchased more Novavax doses (900 M) than any other vaccine in its portfolio 3/ launchandscalefaster.org/covid-19/vacci…
Over 7 billion Covid-19 vaccine doses have been produced globally to date, with >1.35 billion more doses produced each month now.
Sinovac and Sinopharm produce the greatest number of vaccines monthly, with Pfizer and AstraZeneca not far behind. 1/
By the end of this year the world is likely to produce over 12 billion vaccine doses of all vaccine types.
By June 2022 the number produced could reach double that – 24 billion doses (assuming all goes well, and it usually doesn’t) 2/
Even after reserving doses for boosters, Western countries are likely to accumulate large stockpiles of vaccines over the coming months, perhaps as many as 1.2 billion doses by the end of this year.
These “surplus” doses could be redistributed to lower income countries. 3/
Keeping a wary eye on Covid trends in South America. The good: cases/deaths there have come down from devastating peaks a few months back, and there’s progress on vaccinations. The bad: Delta may have only begun to circulate, and questions about vaccine efficacy
Most countries in the region have fully vaccinated between 20 and 40% of their populations; Chile and Uruguay stand out, with >70% fully vaccinated. Countries use a mix of vaccines, mostly Chinese inactivated vaccines (Sinovac and Sinopharm), plus some Pfizer & AstraZeneca
Chinese vaccines have lower effectiveness vs symptomatic disease but protect vs hospitalizations and death.
Chile estimated the Sinovac VE vs. symptomatic Covid at 58%, and 86% vs hospitalization. For Pfizer: 88% and 97%, AZ: 68% and 100%, respectively minsal.cl/wp-content/upl…
Some initial thoughts on full FDA approval of the Pfizer vaccine and what it might mean for vaccine acceptance in the US, based on @KFF polling and policy work
A commonly referenced finding from KFF's vaccine monitor is that 3 in 10 unvaccinated people reported they'd be more likely to get the vaccine upon full FDA approval kff.org/coronavirus-co…
Still, I don't think it means that if unvaccinated people hear the news about full FDA approval 3 in 10 of will all of a sudden decide to get the shot based on that alone.
G20 summit today featured many pledges, promises and proposals to address global gaps in COVID19 vaccine access. We'll have to see how many of these become concrete actions in the weeks and months ahead. reuters.com/world/g20-heal…
Pfizer promised to provide 2 billion doses "at cost" for lower income countries over the next 18 months: 1 billion by the end of this year and another billion by the middle of 2022. reuters.com/business/healt…
.@gavi and J&J announced a purchase agreement of 200 million doses of the J&J vaccine for distribution through COVAX this year gavi.org/news/media-roo…